True North Advisors LLC Has $605,000 Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

True North Advisors LLC raised its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,232 shares of the medical equipment provider’s stock after buying an additional 25 shares during the quarter. True North Advisors LLC’s holdings in Intuitive Surgical were worth $605,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Creekmur Asset Management LLC increased its stake in shares of Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 42 shares during the last quarter. Ridgewood Investments LLC purchased a new position in Intuitive Surgical in the second quarter valued at about $26,000. Able Wealth Management LLC purchased a new stake in shares of Intuitive Surgical during the 4th quarter worth about $28,000. Delos Wealth Advisors LLC lifted its holdings in shares of Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 57 shares during the last quarter. Finally, LRI Investments LLC acquired a new stake in shares of Intuitive Surgical during the 1st quarter valued at about $30,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. BTIG Research increased their target price on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Morgan Stanley lifted their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Barclays upped their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a report on Thursday, July 18th. JPMorgan Chase & Co. boosted their price objective on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Finally, Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their target price for the company from $380.00 to $510.00 in a report on Friday, August 2nd. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $454.35.

Intuitive Surgical Stock Up 0.0 %

Shares of ISRG stock opened at $480.83 on Wednesday. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $496.48. The firm has a market cap of $170.55 billion, a price-to-earnings ratio of 86.78, a PEG ratio of 5.39 and a beta of 1.39. The stock has a 50-day moving average price of $478.06 and a 200 day moving average price of $433.29.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the previous year, the firm posted $1.18 earnings per share. Intuitive Surgical’s revenue for the quarter was up 14.5% compared to the same quarter last year. Sell-side analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Robert Desantis sold 1,413 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $438.60, for a total value of $619,741.80. Following the sale, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,414,931.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the transaction, the director now owns 821 shares in the company, valued at $402,519.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Robert Desantis sold 1,413 shares of the company’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $438.60, for a total value of $619,741.80. Following the sale, the executive vice president now owns 5,506 shares in the company, valued at $2,414,931.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,120 shares of company stock worth $25,528,753. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.